Repare Therapeutics Inc
Change company Symbol lookup
Select an option...
RPTX Repare Therapeutics Inc
DIDIY DiDi Global Inc
GOTU Gaotu Techedu Inc
EFC Ellington Financial Inc
FITB Fifth Third Bancorp
CO Global Cord Blood Corp
KRP Kimbell Royalty Partners LP
VIRX Viracta Therapeutics Inc
ONFO Onfolio Holdings Inc

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Repare Therapeutics Inc. is a clinical-stage precision oncology company engaged in developing synthetic lethality (SL) to the discovery and development of novel therapeutics. The Company uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. Using its SNIPRx platform, the Company is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. The Company’s product pipelines include Camonsertib ATR Inhibitor, RP-6306 PKMYT1 Inhibitor and RP-2119 Pol Inhibitor. Its RP-6306 is being developed as a highly potent and selective PKMYT1 inhibitor that preferentially kills tumor cells overexpressing CCNE1.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.